Výsledky vyhledávání - Caicun Zhou
- Zobrazuji výsledky 1 - 20 z 144
- Přejít na další stránku
-
1
-
2
Lung cancer in never smokers—the East Asian experience Autor Fei Zhou, Caicun Zhou
Vydáno 2018Revisão -
3
-
4
Role of IL-2 in cancer immunotherapy Autor Tao Jiang, Caicun Zhou, Shengxiang Ren
Vydáno 2016Revisão -
5
The cutting-edge progress of immune-checkpoint blockade in lung cancer Autor Fei Zhou, Meng Qiao, Caicun Zhou
Vydáno 2020Revisão -
6
-
7
Non‐small cell lung cancer in China Autor Peixin Chen, Yunhuan Liu, Yaokai Wen, Caicun Zhou
Vydáno 2022Revisão -
8
-
9
-
10
-
11
-
12
-
13
-
14
Single‐cell transcriptomics reveal metastatic <i>CLDN4</i>+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non‐small‐cell lung cance... Autor Xiaoshen Zhang, Xuanhe Wang, Yaokai Wen, Chen Shen, Caicun Zhou, Fengying Wu
Vydáno 2024Artigo -
15
PD-L1 Expression in Lung Cancer Autor Hui Yu, Theresa A. Boyle, Caicun Zhou, David L. Rimm, Fred R. Hirsch
Vydáno 2016Revisão -
16
TIM-3, a promising target for cancer immunotherapy Autor Yayi He, Jie Cao, Chao Zhao, Xuefei Li, Caicun Zhou, Fred R. Hirsch
Vydáno 2018Revisão -
17
-
18
-
19
-
20
Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs Autor Qinghua Xu, Fei Zhou, Hui Liu, Tao Jiang, Xuefei Li, Yaping Xu, Caicun Zhou
Vydáno 2018Artigo
Vyhledávací nástroje:
Související témata
Medicine
Internal medicine
Oncology
Cancer
Lung cancer
Cancer research
Biology
Chemotherapy
Epidermal growth factor receptor
Immunotherapy
Gene
Biochemistry
Genetics
Confidence interval
Adenocarcinoma
Immunology
Pathology
Gastroenterology
Gefitinib
Erlotinib
Hazard ratio
Clinical endpoint
Immune system
Cisplatin
Randomized controlled trial
Surgery
Clinical trial
Mutation
Progression-free survival
Adverse effect